Xbrane Biopharma AB (XBRANE) - Total Liabilities

Latest as of March 2026: Skr120.60 Million SEK ≈ $12.98 Million USD

Based on the latest financial reports, Xbrane Biopharma AB (XBRANE) has total liabilities worth Skr120.60 Million SEK (≈ $12.98 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Xbrane Biopharma AB (XBRANE) equity growth momentum to track the company's year-over-year net asset growth rate.

Xbrane Biopharma AB - Total Liabilities Trend (2012–2025)

This chart illustrates how Xbrane Biopharma AB's total liabilities have evolved over time, based on quarterly financial data. See Xbrane Biopharma AB free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Xbrane Biopharma AB Competitors by Total Liabilities

The table below lists competitors of Xbrane Biopharma AB ranked by their total liabilities.

Company	Country	Total Liabilities
Ucloudlink Group Inc NASDAQ:UCL	USA	$36.39 Million
Oversea Enterprise Bhd KLSE:0153	Malaysia	RM118.76 Million
Allied Gaming & Entertainment Inc. NASDAQ:AGAE	USA	$35.21 Billion
JV SPAC Acquisition Corp. Class A Ordinary Share NASDAQ:JVSA	USA	$2.33 Million
Smartlink Holdings Limited NSE:SMARTLINK	India	Rs639.48 Million
Maniker KO:027740	Korea	₩116.88 Billion
Trajan Group Holdings Ltd AU:TRJ	Australia	AU$89.27 Million
P&H Tech Co. Ltd. KQ:239890	Korea	₩12.49 Billion

Liability Composition Analysis (2012–2025)

This chart breaks down Xbrane Biopharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Xbrane Biopharma AB (XBRANE) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.03	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.22	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.18	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Xbrane Biopharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Xbrane Biopharma AB (2012–2025)

The table below shows the annual total liabilities of Xbrane Biopharma AB from 2012 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr110.97 Million ≈ $11.94 Million	-82.49%
2024-12-31	Skr633.89 Million ≈ $68.22 Million	+31.47%
2023-12-31	Skr482.17 Million ≈ $51.89 Million	+81.52%
2022-12-31	Skr265.63 Million ≈ $28.59 Million	+3.48%
2021-12-31	Skr256.69 Million ≈ $27.62 Million	+24.57%
2020-12-31	Skr206.06 Million ≈ $22.17 Million	+33.27%
2019-12-31	Skr154.62 Million ≈ $16.64 Million	-8.95%
2018-12-31	Skr169.81 Million ≈ $18.27 Million	+652.89%
2017-12-31	Skr22.55 Million ≈ $2.43 Million	+108.67%
2016-12-31	Skr10.81 Million ≈ $1.16 Million	-61.15%
2015-12-31	Skr27.82 Million ≈ $2.99 Million	+7020.88%
2014-12-31	Skr390.70K ≈ $42.05K	-22.70%
2013-12-31	Skr505.44K ≈ $54.39K	-11.15%
2012-12-31	Skr568.90K ≈ $61.22K	--

About Xbrane Biopharma AB

ST:XBRANE Sweden Biotechnology

Market Cap

$22.73 Million

Skr211.20 Million SEK

Market Cap Rank

#24653 Global

#493 in Sweden

Share Price

Skr10.25

Change (1 day)

+0.99%

52-Week Range

Skr0.24 - Skr23.30

All Time High

Skr176.00